StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Despite some positive results, the overall drug efficacy was not demonstrated across all patients. The significant drop in stock price reflects investor disappointment and concerns over future trials.
What happened, with direct paths to the underlying reporting
INMB's stock is down 59%, trading at $2.14. Volume spiked to 23.2 million, significantly above average. Phase 2 trial results showed cognitive benefits for XPro in OBAD patients. INMB plans to file for Breakthrough Therapy Designation with the FDA. Company aims to define pivotal trial path in Q4 2025.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.